US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Evofem Biosciences, Inc.

0.0090

+0.00011.12%

Volume:222.47K

Turnover:1.99K

Market Cap:1.02M

PE:0.00

High:0.0090

Open:0.0090

Low:0.0088

Close:0.0089

Loading ...

Overview Company News Filings

Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Evofem announces license and supply agreement with Windtree Therapeutics

BRIEF-Evofem Expects Significant Reduction In PHEXXI Manufacturing Cost Through Agreement With Windtree Therapeutics

Evofem Expects Significant Reduction in Phexxi Manufacturing Cost Through Agreement With Windtree Therapeutics

THOMSON REUTERS

Evofem Biosciences Inc - Cost to Manufacture Phexxi Will Decrease by 55% - 60%

THOMSON REUTERS

Evofem Reports Fourth Consecutive Year of Net Sales Growth

THOMSON REUTERS

Press Release: Evofem Reports Fourth Consecutive Year of Net Sales Growth

BUZZ-Windtree Therapeutics rises on licensing deal for birth control vaginal gel

Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech With an FDA Approved Product

THOMSON REUTERS

Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EVFM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EVFM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVFM\",,,,,undefined,":{"symbol":"EVFM","market":"US","secType":"STK","nameCN":"Evofem Biosciences, Inc.","latestPrice":0.009,"timestamp":1744920000000,"preClose":0.0089,"halted":0,"volume":222472,"delay":15,"floatShares":113354642,"shares":113356354,"eps":-19.076116,"marketStatus":"Closed","change":0.0001,"latestTime":"04-17 16:00:00 EDT Delay","open":0.009,"high":0.009,"low":0.0088,"amount":1994.3620999999998,"amplitude":0.022472,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-19.076116,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":5,"adr":0,"exchange":"OTCQB","adjPreClose":0.0089,"volumeRatio":0.894248},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVFM\",,,,,undefined,":{"symbol":"EVFM","floatShares":113354642,"roa":"-27.94%","roe":"-387.27%","lyrEps":-23.631594,"volumeRatio":0.894248,"shares":113356354,"dividePrice":0,"high":0.009,"amplitude":0.022472,"preClose":0.0089,"low":0.0088,"week52Low":0.006,"pbRate":"-0.01","psRate":"0.05","week52High":0.02,"institutionHeld":0,"latestPrice":0.009,"eps":-19.076116,"divideRate":0,"volume":222472,"delay":15,"ttmEps":-19.076116,"open":0.009,"prevYearClose":0.0099,"prevWeekClose":0.0095,"prevMonthClose":0.0088,"prevQuarterClose":0.0088,"fiveDayClose":0.0095,"twentyDayClose":0.0093,"sixtyDayClose":0.01},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVFM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528719078","title":"Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™","url":"https://stock-news.laohu8.com/highlight/detail?id=2528719078","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528719078?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:15","pubTimestamp":1744892100,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., April 17, 2025----Aditxt, Inc.  , a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune, Inc. .Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Officer of Adimune, Inc.Event Details:Title: Aditxt Weekly UpdateDate: Friday, May 2, 2025Time: 11:30 a.m. ETLocation: Virtual Registration: Click here to register. ADI-100 is designed to work through precision immune reprogramming, downregulating pro-inflammatory cytokines while upregulating anti-inflammatory cytokine","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dr-charles-howe-mayo-clinic-121500791.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EVFM","LU0006061336.USD","LU0162691827.USD","BAX","BK4504","ADTX","LU1267930490.SGD","BK4139","LU0211328371.USD","LU0310799852.SGD","BK4585","LU2098885051.SGD","BK4007","BK4588","LU0211327993.USD","BK4082","LU1303367103.USD","BK4584","LU0072461881.USD"],"gpt_icon":0},{"id":"2527948216","title":"Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527948216","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527948216?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:15","pubTimestamp":1744805700,"startTime":"0","endTime":"0","summary":"Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic Endometriosis Test, a potential non-invasive approach to surgical diagnosis for endometriosis. MOUNTAIN VIEW, Calif., April 16, 2025----Aditxt, Inc.  , a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. , has received Institutional Review Board  approval from WCG Clinical to initiate a prospective clinical study evaluating the Mitomic Endometriosis Test , a novel blood-based diagnostic designed to aid in the early detection of endometriosis.Endometriosis affects an estimated 1 in 10 women globally, yet diagnosis can take 7 to 10 years on average due to the invasive nature of laparoscopy and lack of accurate, non-invasive tests. This diagnostic delay can lead to chronic pain, infertility and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-subsidiary-pearsanta-receives-irb-121500094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4162","BK4007","BK4585","BK4584","LU1291159041.SGD","BK4588","LU1989772923.USD","LU1496350502.SGD","EVFM","LU1989771016.USD","MET","BK4139","ADTX","LU1989772840.SGD"],"gpt_icon":0},{"id":"2527418139","title":"Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2527418139","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527418139?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"WARRINGTON, Pa., April  15, 2025  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage inno","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/15/3061660/0/en/Windtree-Therapeutics-Reports-Year-End-2024-Financial-Results-and-Provides-Key-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4584","EVFM","LENZ","BK4007"],"gpt_icon":0},{"id":"2527549911","title":"Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream","url":"https://stock-news.laohu8.com/highlight/detail?id=2527549911","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527549911?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"MIAMI, April 15, 2025  -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-81-110000154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["URG","BK4017","SBC","PSQ","TQQQ","BK4007","ELRRF","UURAF","NVA","QID","HGRAF","SEVCF","BK4075","SQQQ","BK4168","MNQmain","BK4023","PSQH","BK4213","GOVX","BIXT",".IXIC","USEG","CLNN","NVA.AU","OMEX","OPWEF","BK4135","QLD","BENF","CIA","BK4584","TSYW.SI","BK4077","NVAWW","USJW.SI","BK4139","BK4162","EVFM","ASBP","BK4124","BNZI","BK4137","CUAUF","XXII","USAW.SI","NVIW.SI","NQmain","BK4583","BK4196"],"gpt_icon":1},{"id":"2527015710","title":"Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2527015710","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527015710?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:15","pubTimestamp":1744632900,"startTime":"0","endTime":"0","summary":"Findings Further Support the Safety Profile and Immunomodulatory Effects of ADI-100, Adimune’s Lead Therapeutic Candidate for Autoimmune Diseases. The independent study, led by Dr. Sean Pittock and Dr. Charles Howe of the Mayo Clinic’s neuroimmunology team, confirmed that ADI-100 induces immune tolerance to glutamic acid decarboxylase —a key autoantigen implicated in multiple autoimmune conditions, including type 1 diabetes, stiff person syndrome, cerebellar ataxia, and autoimmune epilepsy.\"These results mark an important milestone not only for Adimune’s platform but also for Aditxt’s broader vision of transforming the way we approach autoimmune diseases,\" said Amro Albanna, co-founder and CEO of Aditxt. \"We believe that autoimmunity represents one of the most underserved and challenging areas of medicine. ADI-100’s potential ability to restore immune tolerance without broad immunosuppression is a meaningful step toward safer, more targeted treatments.\". Immune Modulation at the Cellul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-subsidiary-adimune-announces-positive-121500858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0072461881.USD","BAX","LU2098885051.SGD","ADTX","BK4139","LU1303367103.USD","BK4584","BK4082","LU0006061336.USD","LU0310799852.SGD","BK4178","BK4585","LU1267930490.SGD","LU0211327993.USD","BK4504","BK4007","LU0162691827.USD","BK4588","EVFM","AAN","LU0211328371.USD"],"gpt_icon":0},{"id":"2526657426","title":"Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2526657426","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526657426?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:15","pubTimestamp":1744373700,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., April 11, 2025----Aditxt, Inc.  , a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will provide key updates on recent events, including:. Aditxt’s recent notice from Nasdaq that it had regained compliance with Nasdaq’s minimum bid price requirement and is therefore in compliance with the Nasdaq Capital Market’s listing requirements. Event Details:Title: Aditxt Weekly UpdateDate: Friday, April 11, 2025Time: 11:30 a.m. ETLocation: Virtual Registration: Click here to register. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to \"Make Promising Innovations Possible Together.\" The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-weekly-highlight-recent-events-121500595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4584","BK4007","LU2210149790.SGD","ADTX",".IXIC","BK4585","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","EVFM","BK4588","BK4139"],"gpt_icon":0},{"id":"2522757405","title":"Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection","url":"https://stock-news.laohu8.com/highlight/detail?id=2522757405","media":"Business Wire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522757405?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:15","pubTimestamp":1743164100,"startTime":"0","endTime":"0","summary":"Event to feature Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt; Chris Mitton, President of Pearsanta; and Dr. Roger Giese, Co-Inventor of the CaSe Platform and Professor Emeritus at Northeastern University. MOUNTAIN VIEW, Calif., March 28, 2025----Aditxt, Inc. , , a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will focus on the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. . The proprietary technology is based on adductomics and is designed to assess early DNA changes that may lead to mutations associated with cancer and other illnesses. The discussion will explore the platform’s role in advancing Pearsanta’s mission to address cancer through early detection and prevention.Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/upcoming-aditxt-weekly-highlight-pearsanta-121500269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4584","BK4007","ADTX","EVFM","BK4139"],"gpt_icon":0},{"id":"2522805388","title":"Evofem announces license and supply agreement with Windtree Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2522805388","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522805388?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:55","pubTimestamp":1742993732,"startTime":"0","endTime":"0","summary":"Evofem Biosciences (EVFM) announced that it has entered into a License and Supply Agreement with Windtree Therapeutics (WINT), under which Windtree...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evofem-announces-license-and-supply-agreement-with-windtree-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evofem-announces-license-and-supply-agreement-with-windtree-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVFM","BK4584","WINT","BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"2522204808","title":"BRIEF-Evofem Expects Significant Reduction In PHEXXI Manufacturing Cost Through Agreement With Windtree Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2522204808","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522204808?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:49","pubTimestamp":1742993391,"startTime":"0","endTime":"0","summary":"BRIEF-Evofem Expects Significant Reduction In PHEXXI Manufacturing Cost Through Agreement With Windtree TherapeuticsMarch 26 (Reuters) - Evofem Biosciences Inc EVFM.PK:EVOFEM EXPECTS SIGNIFICANT REDUC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90XO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4139","WINT","BK4007","EVFM"],"gpt_icon":1},{"id":"2522808543","title":"Evofem Expects Significant Reduction in Phexxi Manufacturing Cost Through Agreement With Windtree Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2522808543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522808543?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:47","pubTimestamp":1742993244,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90XO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","EVFM","BK4584","WINT"],"gpt_icon":0},{"id":"2522085128","title":"Evofem Biosciences Inc - Cost to Manufacture Phexxi Will Decrease by 55% - 60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522085128","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522085128?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:47","pubTimestamp":1742993244,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90XO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVFM","BK4584","BK4139","BK4007","WINT"],"gpt_icon":0},{"id":"2521272803","title":"Evofem Reports Fourth Consecutive Year of Net Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2521272803","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521272803?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:30","pubTimestamp":1742819405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA4ZTX7F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["WINT","BK4139","EVFM","ADTX","BK4007","BK4584"],"gpt_icon":0},{"id":"2521009728","title":"Press Release: Evofem Reports Fourth Consecutive Year of Net Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2521009728","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521009728?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:30","pubTimestamp":1742819400,"startTime":"0","endTime":"0","summary":"-- 2024 Net Sales Increased 6% to $19.4 Million --. -- Total Operating Expense Reduced 27% from 2023 Levels,-- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and. 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch --. SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. , today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include:. 2) The Company diversified its revenue stream with the July 2024 acquisition of SOLOSEC  2g oral granules, the single-dose oral treatment for bacterial vaginosis and trichomoniasis. Evofem relaunched SOLOSEC in November 2024 through its dedicated U.S. women's health commercial team.-- Evofem, Aditxt, Inc. , and Merger Sub entered into the. \"Our revenue growth and improved loss from operations in 2024 testify to the strength and persistence of this company. Our products matter, our people are tenacious, and we continu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WINT","EVFM"],"gpt_icon":1},{"id":"2521460918","title":"BUZZ-Windtree Therapeutics rises on licensing deal for birth control vaginal gel","url":"https://stock-news.laohu8.com/highlight/detail?id=2521460918","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521460918?lang=en_us&edition=fundamental","pubTime":"2025-03-21 02:20","pubTimestamp":1742494850,"startTime":"0","endTime":"0","summary":"BUZZ-Windtree Therapeutics rises on licensing deal for birth control vaginal gel** Shares of biotechnology firm Windtree Therapeutics WINT.O rise 27.8% to $2.16 in afternoon trading** WINT says it has entered into a licensing deal with Evofem Biosciences EVFM.PK for its birth control vaginal gel, Phexxi     ** WINT will serve as the sourcing partner to Evofem and aims to produce Phexxi at a cheaper cost ** Co says Evofem will maintain ownership of the asset and continue to commercialize Phexxi in the U.S. and internationally** Up to last close, WINT has fallen 99.4% in the past 12 months  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL4N3Q31F3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WINT","BK4139","EVFM","BK4007","BK4584"],"gpt_icon":0},{"id":"2520118453","title":"Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech With an FDA Approved Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2520118453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520118453?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:00","pubTimestamp":1742472001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUA9P2DWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVFM","WINT","BK4584","BK4007","BK4139"],"gpt_icon":0},{"id":"2520532094","title":"Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2520532094","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520532094?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:00","pubTimestamp":1742472000,"startTime":"0","endTime":"0","summary":"Transaction is part of the Company’s new corporate strategy to become a revenue generating biotechWARRINGTON, Pa., March  20, 2025  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/20/3046178/0/en/Windtree-Announces-License-and-Supply-Agreement-to-Become-Sourcing-Partner-for-a-Small-Biotech-with-an-FDA-Approved-Product.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","EVFM","BK4007"],"gpt_icon":0},{"id":"2520528154","title":"Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520528154","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520528154?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:15","pubTimestamp":1742213700,"startTime":"0","endTime":"0","summary":"Evofem CEO Saundra Pelletier will join Aditxt Co-founder and CEO Amro Albanna to discuss status and future plans. MOUNTAIN VIEW, Calif., March 17, 2025----Aditxt, Inc.  , an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today provided a corporate update outlining recent achievements and strategic milestones across its subsidiaries and strategic acquisition initiatives. In addition, the Company will be launching Aditxt Weekly Updates, starting Friday March 21, 2025, and continuing throughout the second quarter of 2025.As Aditxt continues executing its strategic roadmap, the Company remains focused on advancing its subsidiaries toward key commercial milestones while progressing with strategic acquisitions. Below are the latest updates:. Adimune Inc.’s  mission is to address the root causes of autoimmune diseases. By harnessing the body’s natural ability to restore and maintain immune tolerance, Adimune strives to deliver innovative ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-provides-business-status-overview-121500849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4584","ADTX","BK4139","EVFM","IPO","BK4007"],"gpt_icon":0},{"id":"2517786152","title":"Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517786152","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517786152?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:15","pubTimestamp":1741266900,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., March 06, 2025----Aditxt, Inc.  , a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc.,  and its progress in advancing ADI-100, an investigational product candidate to be studied in patients with Psoriasis, Type I Diabetes  and Stiff Person Syndrome.Adimune’s mission is to address the root causes of autoimmune diseases. By harnessing the body’s natural ability to restore and maintain immune tolerance, Adimune strives to deliver innovative solutions that improve lives without the risks of immunosuppression.As a subsidiary of Aditxt, Adimune continues to advance its novel immune modulation therapy, the ADI platform, for autoimmune diseases toward first-in-human clinical trials. Aditxt provides critical support, resources, and infrastructure to drive regulatory and clinical progress, helping move ADI-100, its first product candidate based on the ADI platform, into its next phas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-subsidiary-adimune-ship-drug-131500005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4605","LU0310799852.SGD","LU1244550221.USD","EVFM","LU0072461881.USD","BK4585","LU0162691827.USD","LU1670711123.USD","BK4141","BK4515","LU1861214812.USD","LU0109392836.USD","BK4504","LU0314104364.USD","LU1803068979.SGD","LU1303367103.USD","BK4082","LU0719512351.SGD","LU2458330169.SGD","LU1670710588.SGD","LU0724618433.USD","LU1670711040.USD","BK4007","LU0889565833.HKD","ADTX","LU2237443382.USD","LU1244550577.SGD","LU1642822529.SGD","LU1992135472.HKD","LU2272731782.SGD","BK4561","LU1861219969.SGD","LU0082616367.USD","LU1992135399.USD","BAX","BK4588","LU1978683503.SGD","LU2237443549.SGD","LU2360107325.USD","IE00BD6J9T35.USD","LU2272731600.USD","LU0211327993.USD","IE00BZ199S13.USD","BK4139","LU2237443622.USD","LU2237438978.USD","IE0009356076.USD","ADI","LU0957808578.USD","LU0211328371.USD"],"gpt_icon":0},{"id":"2513329260","title":"Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2513329260","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513329260?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:15","pubTimestamp":1740143700,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., February 21, 2025----Aditxt, Inc.  , a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. , has engaged Dominari Securities LLC as lead underwriter for Pearsanta’s planned initial public offering . The proposed IPO, advised by Dominari Securities, is intended to support Pearsanta’s U.S. and international commercial launch efforts and further advance its Mitomic Technology platform for early cancer detection and diagnosis.Pearsanta is developing a non-invasive blood-based test designed to detect cancer at earlier stages when treatment outcomes are more favorable. The Company’s proprietary Mitomic Technology leverages mitochondrial DNA deletions as biomarkers for disease detection, providing a unique approach to identifying malignancies. We believe that Pearsanta’s biomarker portfolio covers many high-clinical need cancers, with potential applications outside oncology.Pearsanta con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-subsidiary-pearsanta-engages-dominari-131500100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4584","IPO","ADTX","BK4139","BK4007","EVFM"],"gpt_icon":0},{"id":"2511654769","title":"Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2511654769","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511654769?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:15","pubTimestamp":1739452500,"startTime":"0","endTime":"0","summary":"Co-founder and CEO Amro Albanna to Provide a Company Update Followed by Q&A Session. MOUNTAIN VIEW, Calif., February 13, 2025----Aditxt, Inc.  , a social innovation platform dedicated to accelerating promising health innovations, today announced that it will host a virtual Fireside Chat on Friday, February 21, 2025, at 11:30 AM Eastern Time. The event will feature Amro Albanna, CEO of Aditxt, who will provide updates on key corporate developments, including the status of current subsidiaries, potential transactions, and notable advancements in the Company's pipeline.During the session, Amro Albanna will discuss developments within Adimune, Inc., a subsidiary focused on autoimmunity including the treatment of Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-host-fireside-chat-friday-131500731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4584","HST","EML","EVFM","BK4007","BK4181","BK4144","ADTX","BK4161","BK4218","BK4139","IPO","AM","BK4585"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVFM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-08-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-11-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-08-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1691985600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVFM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVFM\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVFM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVFM","date":"2022-08-05","current":-0.166395,"percent":0.950893,"low":-6.597859,"twenty":-2.250243,"median":-1.289012,"eighty":-0.728459,"high":-0.031142,"avg":-1.49806,"sd":1.032744,"marketCap":31769672},"quantilePoints":[{"date":"2020-04-17","current":-3.150852,"twenty":-2.171161,"median":-1.353314,"eighty":-0.951877,"marketCap":252172119},{"date":"2020-04-24","current":-3.361736,"twenty":-2.189134,"median":-1.356723,"eighty":-0.959898,"marketCap":269049781},{"date":"2020-05-01","current":-3.105027,"twenty":-2.196323,"median":-1.359933,"eighty":-0.965246,"marketCap":248504655},{"date":"2020-05-08","current":-3.077361,"twenty":-2.210702,"median":-1.361739,"eighty":-0.965246,"marketCap":249607793},{"date":"2020-05-15","current":-3.212225,"twenty":-2.250243,"median":-1.367917,"eighty":-0.965477,"marketCap":260546780},{"date":"2020-05-22","current":-3.05897,"twenty":-2.282595,"median":-1.374379,"eighty":-0.967209,"marketCap":248116113},{"date":"2020-05-29","current":-3.347089,"twenty":-2.295536,"median":-1.374379,"eighty":-0.967209,"marketCap":271485767},{"date":"2020-06-05","current":-3.192132,"twenty":-2.340109,"median":-1.375692,"eighty":-0.967209,"marketCap":258917031},{"date":"2020-06-12","current":-2.813714,"twenty":-2.417973,"median":-1.380547,"eighty":-0.969916,"marketCap":228223193},{"date":"2020-06-19","current":-2.79431,"twenty":-2.467359,"median":-1.385578,"eighty":-0.970593,"marketCap":226649240},{"date":"2020-06-26","current":-2.804012,"twenty":-2.565679,"median":-1.393527,"eighty":-0.974828,"marketCap":227436217},{"date":"2020-07-02","current":-2.891334,"twenty":-2.705047,"median":-1.405552,"eighty":-0.975919,"marketCap":234519005},{"date":"2020-07-10","current":-2.988359,"twenty":-2.741698,"median":-1.410607,"eighty":-0.977097,"marketCap":242388771},{"date":"2020-07-17","current":-2.813714,"twenty":-2.798191,"median":-1.413949,"eighty":-0.978316,"marketCap":228223193},{"date":"2020-07-24","current":-2.842822,"twenty":-2.813714,"median":-1.442913,"eighty":-0.981662,"marketCap":230584123},{"date":"2020-07-31","current":-2.901037,"twenty":-2.817595,"median":-1.451503,"eighty":-0.984607,"marketCap":235305982},{"date":"2020-08-07","current":-2.422033,"twenty":-2.817595,"median":-1.463115,"eighty":-0.986068,"marketCap":238151237},{"date":"2020-08-14","current":-2.587359,"twenty":-2.813714,"median":-1.465468,"eighty":-0.987517,"marketCap":254407295},{"date":"2020-08-21","current":-2.521229,"twenty":-2.813714,"median":-1.476662,"eighty":-0.988581,"marketCap":247904872},{"date":"2020-08-28","current":-2.587359,"twenty":-2.807893,"median":-1.489827,"eighty":-0.990273,"marketCap":254407295},{"date":"2020-09-04","current":-2.884947,"twenty":-2.813714,"median":-1.498338,"eighty":-0.994499,"marketCap":283668198},{"date":"2020-09-11","current":-1.735928,"twenty":-2.813714,"median":-1.501322,"eighty":-0.997697,"marketCap":170688600},{"date":"2020-09-18","current":-2.008717,"twenty":-2.809833,"median":-1.509563,"eighty":-0.999374,"marketCap":197511094},{"date":"2020-09-25","current":-1.84339,"twenty":-2.804012,"median":-1.510164,"eighty":-1.000561,"marketCap":181255037},{"date":"2020-10-02","current":-2.116179,"twenty":-2.804012,"median":-1.525046,"eighty":-1.001911,"marketCap":208077532},{"date":"2020-10-09","current":-2.397234,"twenty":-2.804012,"median":-1.542965,"eighty":-1.001911,"marketCap":235712829},{"date":"2020-10-16","current":-2.364169,"twenty":-2.800131,"median":-1.54827,"eighty":-1.001911,"marketCap":232461617},{"date":"2020-10-23","current":-2.083114,"twenty":-2.79431,"median":-1.561817,"eighty":-1.001911,"marketCap":204826320},{"date":"2020-10-30","current":-1.959119,"twenty":-2.790429,"median":-1.571494,"eighty":-1.002218,"marketCap":192634277},{"date":"2020-11-06","current":-2.025249,"twenty":-2.781758,"median":-1.588912,"eighty":-1.003413,"marketCap":199136700},{"date":"2020-11-13","current":-1.555597,"twenty":-2.774179,"median":-1.602459,"eighty":-1.004884,"marketCap":178003826},{"date":"2020-11-20","current":-1.655041,"twenty":-2.763731,"median":-1.588912,"eighty":-1.007151,"marketCap":189383066},{"date":"2020-11-27","current":-1.626629,"twenty":-2.753559,"median":-1.609695,"eighty":-1.009743,"marketCap":186131854},{"date":"2020-12-04","current":-1.576906,"twenty":-2.745522,"median":-1.591113,"eighty":-1.010116,"marketCap":180442234},{"date":"2020-12-11","current":-1.527184,"twenty":-2.743329,"median":-1.573429,"eighty":-1.011438,"marketCap":174752614},{"date":"2020-12-18","current":-1.47391,"twenty":-2.736486,"median":-1.569803,"eighty":-1.012602,"marketCap":168656593},{"date":"2020-12-24","current":-1.676351,"twenty":-2.729051,"median":-1.570648,"eighty":-1.013448,"marketCap":191821474},{"date":"2020-12-31","current":-1.726073,"twenty":-2.720643,"median":-1.573429,"eighty":-1.014445,"marketCap":197511094},{"date":"2021-01-08","current":-1.797105,"twenty":-2.718666,"median":-1.575364,"eighty":-1.014684,"marketCap":205639123},{"date":"2021-01-15","current":-1.889446,"twenty":-2.71669,"median":-1.596786,"eighty":-1.016196,"marketCap":216205560},{"date":"2021-01-22","current":-1.995994,"twenty":-2.705047,"median":-1.609695,"eighty":-1.017121,"marketCap":228397603},{"date":"2021-01-29","current":-1.882343,"twenty":-2.685112,"median":-1.620009,"eighty":-1.018306,"marketCap":215392757},{"date":"2021-02-05","current":-2.450598,"twenty":-2.681055,"median":-1.620116,"eighty":-1.018566,"marketCap":280416986},{"date":"2021-02-11","current":-2.507423,"twenty":-2.672813,"median":-1.632445,"eighty":-1.021168,"marketCap":286919409},{"date":"2021-02-19","current":-3.366908,"twenty":-2.71669,"median":-1.651829,"eighty":-1.024811,"marketCap":385268555},{"date":"2021-02-26","current":-2.848376,"twenty":-2.745246,"median":-1.655041,"eighty":-1.029338,"marketCap":325933946},{"date":"2021-03-05","current":-1.867672,"twenty":-2.747677,"median":-1.663725,"eighty":-1.032121,"marketCap":265786535},{"date":"2021-03-12","current":-1.676293,"twenty":-2.745246,"median":-1.660162,"eighty":-1.035221,"marketCap":238551624},{"date":"2021-03-19","current":-1.588682,"twenty":-2.743329,"median":-1.655041,"eighty":-1.038349,"marketCap":226083769},{"date":"2021-03-26","current":-1.204757,"twenty":-2.736696,"median":-1.653841,"eighty":-1.038718,"marketCap":171447831},{"date":"2021-04-01","current":-1.233,"twenty":-2.727622,"median":-1.645078,"eighty":-1.04011,"marketCap":175467057},{"date":"2021-04-09","current":-1.240046,"twenty":-2.726572,"median":-1.626629,"eighty":-1.040946,"marketCap":176469726},{"date":"2021-04-16","current":-1.099132,"twenty":-2.71669,"median":-1.619767,"eighty":-1.04998,"marketCap":156416348},{"date":"2021-04-23","current":-1.070949,"twenty":-2.71669,"median":-1.605319,"eighty":-1.04998,"marketCap":152405672},{"date":"2021-04-30","current":-1.055056,"twenty":-2.697285,"median":-1.589897,"eighty":-1.040946,"marketCap":150143944},{"date":"2021-05-07","current":-0.881622,"twenty":-2.676997,"median":-1.577001,"eighty":-1.04011,"marketCap":125462747},{"date":"2021-05-14","current":-0.740987,"twenty":-2.670023,"median":-1.573429,"eighty":-1.033139,"marketCap":125459522},{"date":"2021-05-21","current":-0.773593,"twenty":-2.664959,"median":-1.570648,"eighty":-1.021948,"marketCap":130980172},{"date":"2021-05-28","current":-0.728459,"twenty":-2.655531,"median":-1.567623,"eighty":-1.014684,"marketCap":123338388},{"date":"2021-06-04","current":-0.795167,"twenty":-2.64853,"median":-1.5627,"eighty":-1.010667,"marketCap":134632945},{"date":"2021-06-11","current":-0.94781,"twenty":-2.640264,"median":-1.559356,"eighty":-1.003779,"marketCap":160477457},{"date":"2021-06-18","current":-1.047104,"twenty":-2.607198,"median":-1.555597,"eighty":-1.003779,"marketCap":177289381},{"date":"2021-06-25","current":-1.083211,"twenty":-2.587359,"median":-1.554323,"eighty":-1.003779,"marketCap":183402808},{"date":"2021-07-02","current":-0.992944,"twenty":-2.577755,"median":-1.54827,"eighty":-1.003779,"marketCap":168119241},{"date":"2021-07-08","current":-0.868645,"twenty":-2.571247,"median":-1.543397,"eighty":-1.001923,"marketCap":147073769},{"date":"2021-07-16","current":-0.830462,"twenty":-2.570827,"median":-1.534287,"eighty":-1.001911,"marketCap":140608820},{"date":"2021-07-23","current":-0.837683,"twenty":-2.569976,"median":-1.527184,"eighty":-0.997201,"marketCap":141831505},{"date":"2021-07-30","current":-0.79598,"twenty":-2.566348,"median":-1.527184,"eighty":-0.989357,"marketCap":134770497},{"date":"2021-08-05","current":-0.721238,"twenty":-2.565456,"median":-1.525046,"eighty":-0.985216,"marketCap":122115703},{"date":"2021-08-13","current":-0.777143,"twenty":-2.558807,"median":-1.510765,"eighty":-0.977482,"marketCap":116628902},{"date":"2021-08-20","current":-0.693957,"twenty":-2.535025,"median":-1.509563,"eighty":-0.970593,"marketCap":104144873},{"date":"2021-08-26","current":-0.857569,"twenty":-2.527842,"median":-1.509563,"eighty":-0.967886,"marketCap":128698851},{"date":"2021-09-03","current":-0.906177,"twenty":-2.522882,"median":-1.501822,"eighty":-0.966863,"marketCap":135993649},{"date":"2021-09-10","current":-0.876599,"twenty":-2.521229,"median":-1.500822,"eighty":-0.963107,"marketCap":131554687},{"date":"2021-09-17","current":-0.840815,"twenty":-2.51909,"median":-1.498725,"eighty":-0.951877,"marketCap":126184474},{"date":"2021-09-24","current":-0.807824,"twenty":-2.515298,"median":-1.49021,"eighty":-0.949203,"marketCap":121233324},{"date":"2021-10-01","current":-0.76387,"twenty":-2.512963,"median":-1.485821,"eighty":-0.94602,"marketCap":114636965},{"date":"2021-10-06","current":-0.761491,"twenty":-2.512963,"median":-1.483516,"eighty":-0.944019,"marketCap":114279986},{"date":"2021-10-15","current":-0.741324,"twenty":-2.509639,"median":-1.470856,"eighty":-0.935834,"marketCap":111253421},{"date":"2021-10-22","current":-0.733671,"twenty":-2.500827,"median":-1.466227,"eighty":-0.933578,"marketCap":110104878},{"date":"2021-10-29","current":-0.716089,"twenty":-2.49643,"median":-1.463115,"eighty":-0.930358,"marketCap":107466334},{"date":"2021-11-05","current":-0.739117,"twenty":-2.49147,"median":-1.455373,"eighty":-0.92436,"marketCap":110922261},{"date":"2021-11-12","current":-0.728355,"twenty":-2.482486,"median":-1.447004,"eighty":-0.920137,"marketCap":109307125},{"date":"2021-11-19","current":-0.386369,"twenty":-2.475346,"median":-1.419951,"eighty":-0.911743,"marketCap":75046683},{"date":"2021-11-26","current":-0.368646,"twenty":-2.470234,"median":-1.413372,"eighty":-0.910828,"marketCap":71604324},{"date":"2021-12-03","current":-0.345128,"twenty":-2.465921,"median":-1.409387,"eighty":-0.907248,"marketCap":67036265},{"date":"2021-12-10","current":-0.403167,"twenty":-2.463597,"median":-1.40309,"eighty":-0.905738,"marketCap":78309582},{"date":"2021-12-17","current":-0.313295,"twenty":-2.456306,"median":-1.389572,"eighty":-0.903748,"marketCap":60853071},{"date":"2021-12-23","current":-0.34748,"twenty":-2.450022,"median":-1.381831,"eighty":-0.902029,"marketCap":67493071},{"date":"2021-12-31","current":-0.319174,"twenty":-2.445888,"median":-1.378837,"eighty":-0.897011,"marketCap":61995086},{"date":"2022-01-07","current":-0.336561,"twenty":-2.438566,"median":-1.374379,"eighty":-0.890009,"marketCap":65372187},{"date":"2022-01-14","current":-0.330546,"twenty":-2.435259,"median":-1.374379,"eighty":-0.887406,"marketCap":64203917},{"date":"2022-01-21","current":-0.359744,"twenty":-2.422033,"median":-1.373004,"eighty":-0.88461,"marketCap":69875182},{"date":"2022-01-28","current":-0.344601,"twenty":-2.410537,"median":-1.364205,"eighty":-0.879684,"marketCap":66933925},{"date":"2022-02-04","current":-0.364261,"twenty":-2.408407,"median":-1.361316,"eighty":-0.876997,"marketCap":70752685},{"date":"2022-02-11","current":-0.35121,"twenty":-2.407979,"median":-1.360635,"eighty":-0.873952,"marketCap":68217678},{"date":"2022-02-18","current":-0.3999,"twenty":-2.4055,"median":-1.357152,"eighty":-0.868989,"marketCap":77675059},{"date":"2022-02-25","current":-0.401239,"twenty":-2.4055,"median":-1.354255,"eighty":-0.866236,"marketCap":77935059},{"date":"2022-03-04","current":-0.423267,"twenty":-2.4055,"median":-1.3492,"eighty":-0.857291,"marketCap":82213674},{"date":"2022-03-11","current":-0.320697,"twenty":-2.398887,"median":-1.346995,"eighty":-0.853506,"marketCap":65804496},{"date":"2022-03-18","current":-0.329119,"twenty":-2.397234,"median":-1.344895,"eighty":-0.847851,"marketCap":67532661},{"date":"2022-03-25","current":-0.325812,"twenty":-2.388918,"median":-1.342548,"eighty":-0.840765,"marketCap":66854009},{"date":"2022-04-01","current":-0.301935,"twenty":-2.383963,"median":-1.338645,"eighty":-0.83736,"marketCap":61954723},{"date":"2022-04-08","current":-0.227428,"twenty":-2.374597,"median":-1.333793,"eighty":-0.827311,"marketCap":46666484},{"date":"2022-04-14","current":-0.208602,"twenty":-2.367475,"median":-1.327882,"eighty":-0.818669,"marketCap":42803424},{"date":"2022-04-22","current":-0.177964,"twenty":-2.354249,"median":-1.324122,"eighty":-0.811433,"marketCap":36516842},{"date":"2022-04-29","current":-0.158072,"twenty":-2.337716,"median":-1.320898,"eighty":-0.80387,"marketCap":32435119},{"date":"2022-05-06","current":-0.09804,"twenty":-2.330036,"median":-1.319106,"eighty":-0.796197,"marketCap":20117060},{"date":"2022-05-13","current":-0.079302,"twenty":-2.325012,"median":-1.317041,"eighty":-0.793147,"marketCap":15141105},{"date":"2022-05-20","current":-0.073245,"twenty":-2.319979,"median":-1.316551,"eighty":-0.779563,"marketCap":13984579},{"date":"2022-05-27","current":-0.067867,"twenty":-2.309914,"median":-1.316029,"eighty":-0.776301,"marketCap":12957856},{"date":"2022-06-03","current":-0.067242,"twenty":-2.299849,"median":-1.310904,"eighty":-0.774424,"marketCap":12838360},{"date":"2022-06-10","current":-0.072366,"twenty":-2.291941,"median":-1.307915,"eighty":-0.769174,"marketCap":13816734},{"date":"2022-06-17","current":-0.056191,"twenty":-2.289784,"median":-1.302231,"eighty":-0.761429,"marketCap":10728507},{"date":"2022-06-24","current":-0.062195,"twenty":-2.288346,"median":-1.300568,"eighty":-0.758763,"marketCap":11874923},{"date":"2022-07-01","current":-0.221009,"twenty":-2.282377,"median":-1.299044,"eighty":-0.754436,"marketCap":42197054},{"date":"2022-07-08","current":-0.244479,"twenty":-2.281505,"median":-1.297414,"eighty":-0.747488,"marketCap":46678157},{"date":"2022-07-15","current":-0.209401,"twenty":-2.275405,"median":-1.296606,"eighty":-0.743702,"marketCap":39980638},{"date":"2022-07-22","current":-0.185295,"twenty":-2.264621,"median":-1.294665,"eighty":-0.739566,"marketCap":35378254},{"date":"2022-07-29","current":-0.137119,"twenty":-2.253837,"median":-1.292774,"eighty":-0.734705,"marketCap":26179907},{"date":"2022-08-05","current":-0.166395,"twenty":-2.250243,"median":-1.289012,"eighty":-0.728459,"marketCap":31769672}],"updateTime":1744939525865}}}